Vaccine最新文献

{"title":"Interleukin 38 reduces antigen-presentation capacity and antibody production after vaccination","authors":"","doi":"10.1016/j.vaccine.2024.126396","DOIUrl":"10.1016/j.vaccine.2024.126396","url":null,"abstract":"<div><div>The mechanisms that underpin low vaccine responses, which can lead to inadequate protection against infection, are still partially unclear. Interleukin (IL)-38 is a member of the IL-1 family, expressed by B cells among others, that regulates inflammatory responses. A recent study shows that IL-38 suppresses plasma cell generation and antibody production upon immune activation.</div><div>We hypothesis that IL-38 affects antigen-presentation capacity of innate immune cells, effecting antibody production. Here, we investigated the effect of recombinant human IL-38 on human peripheral blood mononuclear cells and myeloid-derived DCs regarding cytokine production, phagocytosis, and expression of MCH II and co-stimulatory proteins <em>in vitro</em>, and further relate circulating plasma IL-38 concentrations to antibody responses in a cohort of 75 females aged 18–48 vaccinated with BCG and Tdap-IPV.</div><div>To this end, we found that IL-38 decreased the expression of HLA-DR, HLA-DM, and CD83 on PBMCs, and CD40 and CD86 on MDDCs. IL-38 further impaired phagocytosis capacity of monocytes. Lastly, antibody production against diphtheria toxoids up to eight months post-vaccination was negatively associated with IL-38 plasma concentrations.</div><div>These data suggest that IL-38 could dampen the effectiveness of antigen-presentation and phagocytosis, and could therefore modulate the immunogenicity of some vaccine types.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":null,"pages":null},"PeriodicalIF":4.5,"publicationDate":"2024-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142358480","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"National recommendations for adult pneumococcal vaccination in countries of the WHO regions of Americas, Africa, Eastern Mediterranean, South East Asia, and Western Pacific","authors":"","doi":"10.1016/j.vaccine.2024.126390","DOIUrl":"10.1016/j.vaccine.2024.126390","url":null,"abstract":"<div><h3>Background</h3><div>Adults who are elderly or who have underlying health conditions are at particular risk of <em>Streptococcus pneumoniae</em> infections, and pneumococcal vaccines are available. Nonetheless, only national recommendations from countries of North America and Europe have been previously reviewed in the literature.</div></div><div><h3>Methods</h3><div>Consequently, we aimed to collate national guidelines for adult pneumococcal immunization across the 161 countries within the World Health Organization (WHO) regions—the Americas (except Canada and the United States of America), Africa, Eastern Mediterranean, South East Asia, and Western Pacific—from country-level official websites and documents, from the WHO portal, and from direct contact with public health officials, pertinent governmental sources, or local vaccination experts.</div></div><div><h3>Results</h3><div>For 40.4 % (65/161) of these countries, adult pneumococcal vaccination information was available. Among these 65 with available information, 63.1 % (41/65) include adult pneumococcal vaccination in the national vaccination schedule: 58.5 % (24/41) recommend vaccination both for older adults and for risk groups, while 9.8 % (4/41) recommend it only for older adults, and 31.7 % (13/41) only for risk groups. Of note, among the 13 national risk based-only recommendations, 30.8 % (4/13) are age-dependent and strictly reserved for older adults. The regions where age-based adult pneumococcal vaccination recommendations seem to predominate are South East Asia, Western Pacific, and the Americas. The threshold for age-based pneumococcal vaccination recommendations varies between 50 and 70 years of age. The Americas has the highest proportion of countries with risk-based recommendations. Three-quarters of these countries include PCV and PPV23 in the recommendations, most often given in sequence.</div></div><div><h3>Conclusions</h3><div>Less than half of countries of the five WHO regions analyzed have accessible information on adult pneumococcal vaccination, and only 25.5 % (41/161) of all countries reviewed recommend adult pneumococcal immunization within the national vaccination schedule. Policymakers should consider extending pneumococcal vaccination guidelines—adapted to national priorities for adult healthcare—as based on local age demographics and risk factor predominance.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":null,"pages":null},"PeriodicalIF":4.5,"publicationDate":"2024-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142335644","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sociodemographic determinants of COVID-19 vaccination in adolescents in Stockholm, Sweden","authors":"","doi":"10.1016/j.vaccine.2024.126388","DOIUrl":"10.1016/j.vaccine.2024.126388","url":null,"abstract":"<div><h3>Introduction</h3><div>Limited data exists on sociodemographic differences in vaccination coverage against COVID-19 among adolescents. This study investigated the association of sociodemographic factors and vaccination coverage of adolescents aged 12 to 17 years over the period of the general vaccination recommendation in Stockholm County, Sweden.</div></div><div><h3>Method</h3><div>We conducted a population-based retrospective cross-sectional study of vaccine uptake of at least one dose of a COVID-19 vaccine up until 31 October 2022. We analysed vaccination coverage by sex, age group, underlying medical conditions, household socioeconomic factors, and vaccination status among adults in the household, using stratified analyses and multivariable modified Poisson regression models.</div></div><div><h3>Results</h3><div>The study cohort consisted of 166,634 adolescents out of which 70.3 % (<em>n</em> = 117,185) received at least one dose of a COVID-19 vaccine. In the fully adjusted model, the strongest predictor for not being vaccinated was if all adults in the household were unvaccinated (adjusted relative risk, aRR, 0.11, 95 % CI 0.10–0.12). Lower household education level and having both parents born outside Sweden were similarly negatively associated with vaccination coverage among adolescents. No association was observed between vaccination coverage and being an adolescent with an underlying medical condition (aRR 1.00, 95 % CI 0.99–1.02).</div></div><div><h3>Conclusion</h3><div>Our results emphasise the necessity to address sociodemographic disparities and to engage adolescents at risk through targeted measures with particular emphasis in low-vaccination households in addition to households with lower education and non-Swedish origins in future vaccination program strategies.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":null,"pages":null},"PeriodicalIF":4.5,"publicationDate":"2024-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142335645","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Validation of the Chinese version of the vaccine conspiracy beliefs scale during COVID-19 pandemic and its correlates","authors":"","doi":"10.1016/j.vaccine.2024.126395","DOIUrl":"10.1016/j.vaccine.2024.126395","url":null,"abstract":"<div><h3>Objective</h3><div>To validate the Chinese version of the vaccine conspiracy beliefs scale (VCBS) and to investigate and compare its correlates among healthcare workers and non-healthcare workers during COVID-19 pandemic.</div></div><div><h3>Methods</h3><div>From March 19 to April 05, 2021, a nationwide cross-sectional online survey was administered to Chinese individuals aged 16 and above. The study aimed to assess the reliability and validity of the Chinese version of the VCBS. A binary logistic or linear regression model, along with mediation analysis, was employed to explore the relationship between vaccine conspiracy beliefs and its correlates among healthcare workers.</div></div><div><h3>Results</h3><div>The VCBS demonstrated robust psychometric properties, showing satisfactory results from both exploratory and confirmatory factor analyses, strong internal consistency (KR-20 = 0.947), and calibration validity. Measurement invariance (MI) was also observed. Additionally, individuals' vaccine conspiracy beliefs, as measured by the VCBS, mediate the relationship between occupation and COVID-19 vaccine hesitancy (95 % CI [−2.229, −1.060]), as well as COVID-19 (95 % CI [0.096, 0.304]), influenza (95 % CI [0.075, 0.304]), and HPV (95 % CI [0.009, 0.236]) vaccination uptakes.</div></div><div><h3>Conclusion</h3><div>The Chinese adaptation of the VCBS proves adept at assessing vaccine conspiracy beliefs among Chinese individuals aged 16 and above. Notably, the healthcare workers are less likely to exhibit COVID-19 vaccine hesitancy and are more likely to receive COVID-19, influenza, and HPV vaccines. This tendency is partly related to their weaker conspiracy beliefs about vaccination.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":null,"pages":null},"PeriodicalIF":4.5,"publicationDate":"2024-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142335646","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A population database analysis to estimate the varicella vaccine effectiveness in children < 14 years in a high vaccination coverage area from 2004 to 2022","authors":"","doi":"10.1016/j.vaccine.2024.126387","DOIUrl":"10.1016/j.vaccine.2024.126387","url":null,"abstract":"<div><h3>Introduction</h3><div>In the Veneto Region of Italy, universal varicella vaccination (VV) started in 2007 with a two-dose schedule at 12–15 months and 5–6 years of age achieving 90 % coverage in 2019. The study aimed at evaluating the vaccine effectiveness (VE) in children using a primary-care database</div></div><div><h3>Methods</h3><div>This retrospective analysis used Pedianet, a comprehensive database of 73 family paediatricians in the Veneto Region. Incidence rates (IR) of varicella were evaluated in children aged &lt;14 years enrolled since birth, between January 2004 to April 2022. Cases were classified as breakthrough if happening beyond 42 days post-VV. Complications and prescription were evaluated. Subject were followed up from 2004 or the enrollment date, until the end of assistance/study or the first or second VV dose. Kaplan-Meier curves and log-rank tests were used to compare the varicella incidence by vaccination status. Hazard ratios of varicella infection, adjusted (aHRs) for sex, vaccinal status, age group, prematurity and socioeconomic status were estimated with Cox's regression. VE for one and two VV doses was defined as 1-aHR*.</div></div><div><h3>Results</h3><div>36,498 children, followed for 233,508 person-years from 2004 to 2022 experienced 1006 cases of varicella (13 complicated and 35 breakthrough). Younger children had a higher risk of experiencing varicella compared to children aged &gt;7 years, irrespective of their vaccination status. Indeed, the IR increased from 5.5 to 19.5 × 1000 person-years and from 1.1 to 5.4 × 1000 person-years in unvaccinated and vaccinated children aged &lt;12 months versus those aged 5–6 years, respectively. Varicella VE was 83.4 % and 94.7 % in those vaccinated with one and two doses. After six years, the cumulative probability of experiencing varicella was 10.7 % for unvaccinated subjects, and 2.5 % and 0.4 % for those vaccinated with one and two-doses (log-rank test, <em>p</em> &lt; 0.001).</div></div><div><h3>Conclusions</h3><div>Two-dose schedule VV is effective in drastically reduce varicella episodes. Breakthrough varicella episodes remain rare events.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":null,"pages":null},"PeriodicalIF":4.5,"publicationDate":"2024-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142324054","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Vaccines efficacy against infection with circulating feline calicivirus after one single injection: Comparison of Leucofeligen™ FeLV/RCP and Purevax™ RCPFeLV vaccines","authors":"","doi":"10.1016/j.vaccine.2024.126393","DOIUrl":"10.1016/j.vaccine.2024.126393","url":null,"abstract":"<div><div>Feline calicivirus (FCV) is a worldwide pathogen that affects the general health status of cats. The aim of this study was to assess the efficacy of the FCV component of two multivalent commercial vaccines after one injection. The cats assigned to the vaccinated groups received one subcutaneous injection of either the Leucofeligen™ FeLV/RCP (Virbac, France) vaccine or the Purevax™ RCPFeLV (Boehringer Ingelheim, Germany) vaccine. In the control group, the cats did not receive any vaccine. Three weeks after the vaccine injection, all the cats were inoculated with a heterologous calicivirus strain, isolated in the field. The clinical signs of calicivirosis and the viral shedding were assessed. The results demonstrated that Leucofeligen™ FeLV/RCP could protect kittens against FCV infection by reducing clinical signs and viral excretion from 3 weeks after the first injection of primary vaccination, whereas Purevax™ RCPFeLV couldn't offer the same level of protection in similar experimental conditions.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":null,"pages":null},"PeriodicalIF":4.5,"publicationDate":"2024-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142323935","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effectiveness of the ten- and thirteen-valent pneumococcal conjugate vaccines to prevent serotype 19A invasive pneumococcal disease in Quebec, Canada. A Canadian immunization research network (CIRN) study","authors":"","doi":"10.1016/j.vaccine.2024.126379","DOIUrl":"10.1016/j.vaccine.2024.126379","url":null,"abstract":"<div><div>In the province of Quebec, Canada, a 2 + 1 dose pneumococcal conjugate vaccine (PCV) program for children was implemented in 2004. PCV7, PCV10, PCV13 and a mixed PCV10/PCV13 schedule were sequentially used without catch-up. The effectiveness of vaccination schedules to prevent serotype 19A invasive pneumococcal disease (IPD) in &lt;5-year-old children was estimated by the indirect cohort method during 2009–2023. A total of 248 19A IPD cases and 457 IPD controls were included in the analysis. Adjusted vaccine effectiveness (VEa) for ≥1 dose was 57 % [95 %CI: −1 %,82 %] for PCV10 and 62 % [16 %,83 %] for PCV13. VEa for 3 doses was 69 % [17 %,88 %] for PCV10, 76 % [39 %,90 %] for PCV13 and 86 % [64 %,95 %] for the 2PCV10 + 1PCV13 schedule. Protection provided by the PCV10-only schedule tended to be of lower magnitude compared to the two other schedules. The mixed PCV10 + PCV13 schedule showed a protection against 19A IPD at least comparable to that of 3 PCV-13 doses.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":null,"pages":null},"PeriodicalIF":4.5,"publicationDate":"2024-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142324053","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Variant-specific neutralising antibodies levels induced by the PHH-1 V SARS-CoV-2 vaccine (Bimervax®) by HIPRA","authors":"","doi":"10.1016/j.vaccine.2024.126386","DOIUrl":"10.1016/j.vaccine.2024.126386","url":null,"abstract":"<div><div>SARS-CoV-2 virus variants continue to emerge at an alarming rate due to spontaneous genetic mutations, particularly in the spike protein receptor-binding domain (RBD) portion, which render the virus more likely to escape immunity. So far, the immunity obtained through global primary and/or booster immunisation campaigns has been sufficient to protect the population from new emerging variants of the Omicron lineage. The current approach to update vaccines' antigen composition to new variants to boost immunity may not be sustainable in the long term. It might also be potentially redundant if the mutations are giving rise to variants which induce milder infections and existing vaccines, such as Bimervax®, are still sufficiently protective, as Covid is slowly becoming a seasonal illness. Through measuring neutralising antibody titres in sera from subjects boosted with Bimervax®, we have demonstrated the ability of Bimervax® to induce immune responses against a variety of SARS-CoV-2 variants, ranging from earlier variants inducing more serious infections to more recent variants which have been found to produce milder infections.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":null,"pages":null},"PeriodicalIF":4.5,"publicationDate":"2024-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142319310","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Saccharomyces cerevisiae as a platform for vaccination against bovine mastitis","authors":"","doi":"10.1016/j.vaccine.2024.126385","DOIUrl":"10.1016/j.vaccine.2024.126385","url":null,"abstract":"<div><div>Mastitis is a major issue for the dairy industry. Despite multiple attempts, the efficacy of available mastitis vaccines is limited and this has been attributed to their incapacity to trigger robust cell-mediated immunity. Yeasts have recently been identified as promising antigen vectors capable of inducing T-cell responses, surpassing the antibody-biased mechanisms elicited by conventional adjuvanted vaccines. In this study, we combine <em>in vitro, ex vivo,</em> and <em>in vivo</em> approaches to evaluate the potential of the yeast <em>Saccharomyces cerevisiae</em> as a platform for novel vaccines against bovine mastitis. We demonstrate that <em>S. cerevisiae</em> is safe for intramuscular and intramammary immunisation in dairy cows. Vaccination resulted in a significant increase of IFNγ and IL-17 responses against the yeast platform but not against the vaccine antigen. These observations highlight that strategies to counterbalance the immunodominance of <em>S. cerevisiae</em> antigens are necessary for the development of successful vaccine candidates.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":null,"pages":null},"PeriodicalIF":4.5,"publicationDate":"2024-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142319191","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Systematic evaluation of the induction of efficient neutralizing antibodies by recombinant multicomponent subunit vaccines against monkeypox virus","authors":"","doi":"10.1016/j.vaccine.2024.126384","DOIUrl":"10.1016/j.vaccine.2024.126384","url":null,"abstract":"<div><div>Mpox (formerly known as monkeypox), which has symptoms similar to smallpox, is a zoonotic disease caused by the monkeypox virus (MPXV). From 1 January 2022 to 31 March 2024, 117 countries, territories, or areas reported 95,226 laboratory-confirmed cases of Mpox (including 185 deaths) to the World Health Organization. However, as there is no licensed specific MPXV vaccine available globally, the vaccines currently used for mpox prevention are mostly smallpox vaccines. Thus, the rapid development of safe and effective vaccines is urgently required. In the present study, the key MPXV proteins A35, B6R, E8L, A29, M1R, and H3L were expressed and prepared using a prokaryotic expression system (<em>Escherichia coli</em>) and a eukaryotic expression system (yeast), and the fusion antigens A35-A29 and A35-M1R were constructed based on the dimerization characteristics of the A35 protein. By combining the antigens with aluminum hydroxide and CpG adjuvants in different combinations, we developed nine multicomponent MPXV subunit vaccine candidates. Each antigen (10 μg) and fusion antigen (20 μg) were used to immunize the mice. The first two doses produced a mean titer of 10(Petersen et al., 2016 [<span><span>5</span></span>]⁾, and the third dose maintained the same potent antibody-specific response as the previous two immunizations. The protective activity of different antigen combinations was determined using the cell neutralization test of vaccinia virus (VACV), which showed that the subunit vaccine candidates with two to six components (MPXV6/5/4/3a/3b/Fa/2a) had good neutralizing activity, and antigens A35 and M1R could produce neutralizing antibodies against VACV. The neutralizing antibody titer of the fusion antigen MPXVFa (A35-M1R), detected 2 weeks after the second booster dose, was comparable with that of MPXV2a (A35 and M1R). The A35-M1R fusion protein not only provided a high level of protection as a protective antigen but also simplified the preparation of candidate antigens. In summary, we systematically investigated the different protective antigen candidates of MPXV that have been widely studied and provided critical insights into the key protective antigen composition for vaccines, thus establishing a technical and theoretical foundation for the development of MPXV subunit vaccines.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":null,"pages":null},"PeriodicalIF":4.5,"publicationDate":"2024-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142316015","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}